Renzulli C - Search Results

1

Comment on: Rifaximin in the treatment of irritable bowel syndrome. is there a high risk for development of antimicrobial resistance?

Calanni F, Renzulli C, Fogli MV, Barbanti M. Calanni F, et al. Among authors: renzulli c. J Clin Gastroenterol. 2013 Oct;47(9):814. doi: 10.1097/MCG.0b013e3182951b6c. J Clin Gastroenterol. 2013. PMID: 23751850 No abstract available.

2

Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Humans.

Scarpignato C, Dolak W, Lanas A, Matzneller P, Renzulli C, Grimaldi M, Zeitlinger M, Bjarnason I. Scarpignato C, et al. Among authors: renzulli c. Gastroenterology. 2017 Apr;152(5):980-982.e3. doi: 10.1053/j.gastro.2016.12.007. Epub 2016 Dec 19. Gastroenterology. 2017. PMID: 28007576 Free article. Clinical Trial.

3

Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic.

Fornai M, Antonioli L, Pellegrini C, Colucci R, Sacco D, Tirotta E, Natale G, Bartalucci A, Flaibani M, Renzulli C, Ghelardi E, Blandizzi C, Scarpignato C. Fornai M, et al. Among authors: renzulli c. Pharmacol Res. 2016 Feb;104:186-96. doi: 10.1016/j.phrs.2015.12.031. Epub 2015 Dec 30. Pharmacol Res. 2016. PMID: 26747402

4

Rifaximin: beyond the traditional antibiotic activity.

Calanni F, Renzulli C, Barbanti M, Viscomi GC. Calanni F, et al. Among authors: renzulli c. J Antibiot (Tokyo). 2014 Sep;67(9):667-70. doi: 10.1038/ja.2014.106. Epub 2014 Aug 6. J Antibiot (Tokyo). 2014. PMID: 25095806 Review.

5

Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention.

Colucci R, Pellegrini C, Fornai M, Tirotta E, Antonioli L, Renzulli C, Ghelardi E, Piccoli E, Gentile D, Benvenuti L, Natale G, Fulceri F, Palazón-Riquelme P, López-Castejón G, Blandizzi C, Scarpignato C. Colucci R, et al. Among authors: renzulli c. Front Pharmacol. 2018 Nov 29;9:1340. doi: 10.3389/fphar.2018.01340. eCollection 2018. Front Pharmacol. 2018. PMID: 30555323 Free PMC article.

6

Anti-inflammatory and cicatrizing activity of Echinacea pallida Nutt. root extract.

Speroni E, Govoni P, Guizzardi S, Renzulli C, Guerra MC. Speroni E, et al. Among authors: renzulli c. J Ethnopharmacol. 2002 Feb;79(2):265-72. doi: 10.1016/s0378-8741(01)00391-9. J Ethnopharmacol. 2002. PMID: 11801391

7

Effects of rosmarinic acid against aflatoxin B1 and ochratoxin-A-induced cell damage in a human hepatoma cell line (Hep G2).

Renzulli C, Galvano F, Pierdomenico L, Speroni E, Guerra MC. Renzulli C, et al. J Appl Toxicol. 2004 Jul-Aug;24(4):289-96. doi: 10.1002/jat.982. J Appl Toxicol. 2004. PMID: 15300717

8

Effects of trivalent chromium on hepatic CYP-linked monooxygenases in laying hens.

Guerra MC, Renzulli C, Antelli A, Pozzetti L, Paolini M, Speroni E. Guerra MC, et al. Among authors: renzulli c. J Appl Toxicol. 2002 May-Jun;22(3):161-5. doi: 10.1002/jat.853. J Appl Toxicol. 2002. PMID: 12015795

9

Efficacy of different Cynara scolymus preparations on liver complaints.

Speroni E, Cervellati R, Govoni P, Guizzardi S, Renzulli C, Guerra MC. Speroni E, et al. Among authors: renzulli c. J Ethnopharmacol. 2003 Jun;86(2-3):203-11. doi: 10.1016/s0378-8741(03)00076-x. J Ethnopharmacol. 2003. PMID: 12738088

10

Cyanidin-3-O-beta-glucopyranoside, a natural free-radical scavenger against aflatoxin B1- and ochratoxin A-induced cell damage in a human hepatoma cell line (Hep G2) and a human colonic adenocarcinoma cell line (CaCo-2).

Guerra MC, Galvano F, Bonsi L, Speroni E, Costa S, Renzulli C, Cervellati R. Guerra MC, et al. Among authors: renzulli c. Br J Nutr. 2005 Aug;94(2):211-20. doi: 10.1079/bjn20051425. Br J Nutr. 2005. PMID: 16115355

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results